Combining drugs to treat resistant gynecological cancers
Official title: Overcoming treatment-resistant gynecological cancers by combination of DNA damage response inhibitors
Funded at University of Pennsylvania · NIH-10978356 · Data updated 2026-11-12
This study is looking for better ways to treat advanced gynecological cancers that don't respond to current treatments by finding weaknesses in the cancer's genetics and testing new combinations of therapies, which could help doctors create more personalized and effective treatment plans for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 12, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $112,052 |
| NIH project number | 1R50CA283807-01A1 |
| Project ID | NIH-10978356 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with advanced gynecological cancers, particularly those with BRCA mutations, CCNE1 amplification, or ARID1A loss.
✕Less likely to help
Patients with early-stage gynecological cancers or those without the specific genetic markers being targeted may not benefit from this research.
What this research studies
This research focuses on developing new treatment strategies for gynecological cancers that are resistant to current therapies. By identifying genetic vulnerabilities in these cancers, the research aims to combine DNA damage response inhibitors with other targeted therapies to improve patient outcomes. The approach includes testing these combinations in preclinical models and analyzing patient samples to find biomarkers that predict treatment responses. This could lead to more effective and personalized treatment options for patients with advanced gynecological cancers.
Why it matters
Potential benefit: If successful, this research could provide new, effective treatment options for patients with treatment-resistant gynecological cancers.
How similar studies have gone: Other research has shown promise in using targeted therapies for similar genetic vulnerabilities in cancers, indicating a potential for success with this approach.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Xu, Haineng — University of Pennsylvania
- Study coordinator: Xu, Haineng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.